

Martina Zanchetta

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4798264/martina-zanchetta-publications-by-citations.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

16
papers

47
citations

5
h-index

6
g-index

16
ext. papers

69
ext. citations

3.6
avg, IF

1.96
L-index

#	Paper	IF	Citations
16	Simultaneous quantification of palbociclib, ribociclib and letrozole in human plasma by a new LC-MS/MS method for clinical application. <i>PLoS ONE</i> , 2020 , 15, e0228822	3.7	11
15	Development and validation of LC-MS/MS method for imatinib and norimatinib monitoring by finger-prick DBS in gastrointestinal stromal tumor patients. <i>PLoS ONE</i> , 2019 , 14, e0225225	3.7	9
14	A LC-MS/MS method for therapeutic drug monitoring of sorafenib, regorafenib and their active metabolites in patients with hepatocellular carcinoma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020 , 187, 113358	3.5	8
13	Dried Blood Spot Technique Applied in Therapeutic Drug Monitoring of Anticancer Drugs: a Review on Conversion Methods to Correlate Plasma and Dried Blood Spot Concentrations. <i>Pharmaceutical Research</i> , 2021 , 38, 759-778	4.5	7
12	A new high-performance liquid chromatography-tandem mass spectrometry method for the determination of sunitinib and N-desethyl sunitinib in human plasma: Light-induced isomerism overtaking towards therapeutic drug monitoring in clinical routine. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020 , 179, 112949	3.5	5
11	An SPR investigation into the therapeutic drug monitoring of the anticancer drug imatinib with selective aptamers operating in human plasma. <i>Analyst, The</i> , 2021 , 146, 1714-1724	5	5
10	A new dried blood spot LC-MS/MS method for therapeutic drug monitoring of palbociclib, ribociclib, and letrozole in patients with cancer. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021 , 1185, 122985	3.2	2
9	Pharmacogenetic score predicts overall survival, progression-free survival and platinum sensitivity in ovarian cancer. <i>Pharmacogenomics</i> , 2020 , 21, 995-1010	2.6	
8	Development and validation of LC-MS/MS method for imatinib and norimatinib monitoring by finger-prick DBS in gastrointestinal stromal tumor patients 2019 , 14, e0225225		
7	Development and validation of LC-MS/MS method for imatinib and norimatinib monitoring by finger-prick DBS in gastrointestinal stromal tumor patients 2019 , 14, e0225225		
6	Development and validation of LC-MS/MS method for imatinib and norimatinib monitoring by finger-prick DBS in gastrointestinal stromal tumor patients 2019 , 14, e0225225		
5	Development and validation of LC-MS/MS method for imatinib and norimatinib monitoring by finger-prick DBS in gastrointestinal stromal tumor patients 2019 , 14, e0225225		
4	Simultaneous quantification of palbociclib, ribociclib and letrozole in human plasma by a new LC-MS/MS method for clinical application 2020 , 15, e0228822		
3	Simultaneous quantification of palbociclib, ribociclib and letrozole in human plasma by a new LC-MS/MS method for clinical application 2020 , 15, e0228822		
2	Simultaneous quantification of palbociclib, ribociclib and letrozole in human plasma by a new LC-MS/MS method for clinical application 2020 , 15, e0228822		
1	Simultaneous quantification of palbociclib, ribociclib and letrozole in human plasma by a new LC-MS/MS method for clinical application 2020 , 15, e0228822		